Development Drug Trials Drugs RNA 
pharmaphorum
OCTOBER 27, 2020
US biotech BioSig Technologies has abandoned a phase 2 trial of its antiviral drug merimepodib with Gilead’s Veklury in severe COVID-19 patients, after concluding the safety of the combination was in doubt. Moreover, as an orally-active drug merimepodib could also have found a role outside the hospital setting.
Drug Discovery World
MARCH 7, 2023
For International Women’s Day, DDW’s Diana Spencer celebrates some of the women in leadership making an impact on the drug discovery and life sciences sector. Powers taught for more than six years at the National Institutes of Health, on medical product development and commercialisation, and at Georgetown Law School as an adjunct professor.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
JANUARY 17, 2024
Challenges in the Oncology Clinical Trials Space The oncology market is a key growth driver for the pharma industry, with global drug revenues expected to reach US$390 billion by 2027 and the annual number of new cancer cases set to grow from 18 to 27 million by 2040 1,2.
Drug Discovery World
OCTOBER 6, 2022
In pursuit of this, the number of new therapeutics in development has boomed. In the cancer space alone over the last five years, clinical trials have increased 500% for new drugs and new drug combinations. Before drugs make it to market they have to pass through a gauntlet of stages involved in clinical trials.
Pharmaceutical Technology
APRIL 27, 2023
The successful development and deployment of the mRNA-based COVID-19 vaccines has catalysed the biopharma industry and paved the way to expand this drug modality to new therapeutic areas. GlobalData pharmaceutical analysts project that RNA-based gene therapies for oncology will grow from zero in 2022 to $4.6 billion by 2028.
Expert insights. Personalized for you.
98 
Let's personalize your content